← Eichor
Condition: Cytoreductive Surgery Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Cytoreductive Surgery

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Efficacy of Intraoperative Use of 20% Albumin Combined With Ringer Lactate Versus Ringer Lactate During Cytoreductive Su
NA · 7 location(s) · Assistance Publique - Hôpitaux de Paris · NCT06351475Technical Feasibility of Modified Early Post-Operative Intraperitoneal Chemotherapy (mEPIC)
Phase 2 · 1 location(s) · Ciusss de L'Est de l'Île de Montréal · NCT05913674Secondary Interval Cytoreductive Surgery in Platinum-sensitive Recurrent Epithelial Ovarian Cancer
NA · 1 location(s) · The University of Hong Kong · NCT06292286Flat Dose vs. Weight-based IP Chemotherapy for CRS/HIPEC
Phase 2 · 2 location(s) · Prakash Pandalai · NCT04779554Intensive Intraperitoneal Therapy in Advanced Ovarian Cancer
Phase 2 · 1 location(s) · Institut du Cancer de Montpellier - Val d'Aurelle · NCT04282356Secondary Cytoreduction Followed by Chemotherapy Versus Chemotherapy Alone in Relapsed Ovarian Cancer After PARPi Mainte
NA · 1 location(s) · Women's Hospital School Of Medicine Zhejiang University · NCT05607329PHASE II EVALUATION OF CYTOREDUCTION SURGERY AND HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (CRS/HIPEC) IN GASTRIC CANCER
Phase 2 · 1 location(s) · Banner Health · NCT07178808Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Per
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT04847063Metronomic Neoadjuvant Capecitabine and Cyclophosphamide in HUGE Pseudomyxoma Peritonei Patients
Phase 2 · 1 location(s) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · NCT06800391Enhanced Recovery After Surgery (ERAS) in Patients With Peritoneal Carcinomatosis Undergoing Cytoreductive Surgery With
NA · 2 location(s) · Fondazione del Piemonte per l'Oncologia · NCT07493876PROADAPT-ovary/EWOC-2
NA · 11 location(s) · Hospices Civils de Lyon · NCT04284969HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
Phase 2 · 3 location(s) · Children's Hospital Medical Center, Cincinnati · NCT02143830Tissue Oximetry's Measurement in Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy
Phase N/A · 1 location(s) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT06475261Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies
Phase N/A · 1 location(s) · Oslo University Hospital · NCT02073500The PROOV Study: Exploiting the Synergistic Effect of PARP Inhibition With Cisplatin and Hyperthermia During Interval Cy
Phase 1/Phase 2 · 1 location(s) · The Netherlands Cancer Institute · NCT07460180Cukurova Score Validation Study
Phase N/A · 1 location(s) · Cukurova University · NCT06378905Secondary Cytoreductive Surgery After Chemotherapy for Recurrent Epithelial Ovarian Cancer
Phase 2 · 1 location(s) · National Cancer Center, Korea · NCT07171528PROV-MESH: Prophylactic Ovarian Cancer MESH
NA · 1 location(s) · Hospital Vall d'Hebron · NCT07676370Proactive Hemodynamic Management During Cytoreductive Surgery and HIPEC
NA · 1 location(s) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT07070973Ventral Hernias Following Cytoreductive Surgery : Incidence, Risk Factors and Surgical Management.
Phase N/A · 1 location(s) · Jules Bordet Institute · NCT07451483MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurre
Phase 3 · 1 location(s) · National Cancer Institute, Naples · NCT05255471Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for
Phase 1 · 1 location(s) · Stanford University · NCT04609592Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal
Phase 3 · 19 location(s) · M.D. Anderson Cancer Center · NCT04575935Rectosigmoid Lesion Excision vs. Resection: A Non-Inferiority Randomized Comparison in Advanced Ovarian Cancer
NA · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT07616310Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of
EARLY_Phase 1 · 1 location(s) · Ohio State University Comprehensive Cancer Center · NCT05415709Longitudinal Study of CRS/HIPEC for Peritoneal Carcinomatoses
Phase N/A · 2 location(s) · University of Regensburg · NCT04108936Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Can
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT05123807Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer
Phase 2 · 88 location(s) · ARCAGY/ GINECO GROUP · NCT05183984CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery i
Phase 1/Phase 2 · 7 location(s) · TORL Biotherapeutics, LLC · NCT07322094An Audit of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
Phase N/A · 1 location(s) · Tata Memorial Centre · NCT02754115
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.